Indegene
Pharma commercialisation outsourcing
- Last close
- ₹605.15
- 29 Sept 2026 · reference
- 1D · 1M
- −1.3% · +4.5%
- price-only
- Weight
- 1.2%
- 31 Jul 2026 · Aug rank 25
- Thesis review
- 8 Sep 2026
- Why We Own, p48
Approved description
Indegene is the only India-listed pure-play provider of technology-led commercialisation services to life-sciences companies (medical/regulatory writing, omnichannel marketing, pharmacovigilance, MLR review), serving all of the world's top-20 biopharma firms plus 105 active clients (65 at IPO). FY26 revenue Rs 3,510 cr (+23.6%); North America 75%, Europe 22%; ~60% of revenue is output/outcome-priced rather than hourly. It has bolted on BioPharm Communications (USD 104 mn, Oct-2025), Cake Kommunikations (EUR 8.5 mn, Nov-2025) and WARN & Co (2026).
- 01Fastest-growing listed IT-services-type name: Q1FY27 revenue +39.7% (26.5% in USD), FY27 organic growth guided above FY26's 23.6%, with H2 acceleration from a USD 10 mn+ ACV outcome-based deal.
- 02Margin recovery is dated: 16.9% EBITDA margin guided back to 19-20% by Q4FY27 as GTM investments stop and the omnichannel deal's already-incurred costs convert to revenue; IDBI models 29% EPS CAGR FY26-28.
- 03Client base broadening: 105 active clients, USD 1 mn+ accounts 54 (27 at IPO), revenue beyond top-20 clients 33.4% (doubled YoY), NRR 105.8% organic.
- 04AI is a margin lever, not just a threat: ~60% output/outcome-priced revenue means productivity from Cortex/NEXT (50-60% MLR-review cost savings) accrues to Indegene rather than being billed away.
- 05Net cash Rs 1,460 cr (cash & investments) funds tuck-ins; ROCE 18.8% and ~21x FY28E EPS for 18% revenue CAGR (IDBI).
Reference close, with results-period markers
- 1Q Sep-25 end · 30 Sept 2025
- 2Q Dec-25 end · 31 Dec 2025
- 3Q Mar-26 end · 31 Mar 2026
- 4Q Jun-26 end · 30 Jun 2026
Quality score, technicals and Buoyant Score
Computing the scorecard…
Latest quarter · Q Jun-26
| Line (₹ cr) | Q Jun-26 | YoY | QoQ |
|---|---|---|---|
| Net Sales | 1,063 | +39.7% | +6.0% |
| Operating Profit | 174 | +12.3% | +6.1% |
| Net Profit | 116 | 0.0% | +45.5% |
Reported vs internal estimate: internal quarterly estimates are not in the supplied package; consensus feed not licensed. YoY/QoQ per PRD §12.5 (transitions, not %, on non-positive bases).
Position and valuation context
General industrial/consumer/IT preset: growth, margins, ROCE/ROIC, working capital, FCF, net debt; P/E, EV/EBITDA.
Sell-side targets are third-party views, not Buoyant's; the upside is recomputed on our reference close, so it differs from the figure printed at the broker's price date.
Valuation range
No headline target on this page; the book quotes the thesis and the risk rather than a target.
What we watch
- Q3FY27 (Jan-2027): revenue recognition begins on the USD 10 mn+ ACV outcome-based omnichannel contract.
- Q4FY27 (Apr/May-2027): EBITDA margin back in the 19-20% band per guidance.
- Further tuck-in acquisitions using Rs 1,460 cr cash; expansion of the 'Tectonic' largest-client engagement from Germany/Spain to more markets.
- Client concentration: top-20 clients 72% of FY26 revenue; largest client >USD 50 mn run-rate; US drug-pricing/MFN policy cuts to pharma marketing budgets would hit demand.
- Margin execution: EBITDA margin fell from ~20% to 16.9%; employee costs +37% YoY; failure to reach 19-20% by Q4FY27 would compress the multiple.
- AI commoditisation of content/medical-writing workflows, and slower enterprise AI adoption than expected (flagged by management); acquisition integration (BioPharm USD 104 mn) and FX (75% North America).